Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  carmustine
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 42 for your search:
Start Over
Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MCL2004-2, NCT00209222
Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 17 and under
Sponsor: Other
Protocol IDs: CDR0000531687, EURONET-PHL-C1, EU-20703, EUDRACT-2006-000995-33, CCLG-HD-2007-10, NCT00433459
Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: Sor451107ctil, NCT00463463
Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CDR0000633503, GOELAMS-LH2007, GOELAMS-ID-RCB#2007-A01079-44, INCA-RECF0754, AMGEN-GOELAMS-LH2007, NCT00920153
Efficacy of Aprepitant (Emend®) in Children
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 20 and under
Sponsor: Other
Protocol IDs: 0413, NCT01661335
Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2015-00668, BMT CTN 1201, A051301, U10CA180821, NCT02443077
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI, Other
Protocol IDs: 1409.00, NCI-2010-00130, P30CA015704, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
Dose-Intensive Chemotherapy in Combination With Chemoprotected Autologous Stem Cells in Treating Patients With Malignant Gliomas
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2000.00, NCI-2013-00701, 8357, P30CA015704, FHCRC-2000.00, FHCRC-IR-6259, NCT00669669
Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 19 and over
Sponsor: NCI, Other
Protocol IDs: 446-08, NCI-2009-01436, RV-LYM-PI-328, P30CA036727, NCT01035463
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 120003, 12-C-0003, NCT01468311
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: NCI, Other
Protocol IDs: 08179, NCI-2011-03334, P01CA030206, NCT01476839
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2728.00, NCI-2013-01378, P01CA044991, P30CA015704, NCT01921387
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: Under 70
Sponsor: Other
Protocol IDs: 2005LS048, UMN-0508M72589, UMN-MT2004-24, UMN-2005LS048, NCT00345865
Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Other
Protocol IDs: BMA-05-017-ZEV, NCT00438581
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: BMT185, 97623, NCT00481832
Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-Cell Difusse Lymphom
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: GELTAMO-Z-BEAM LDGGB, EudraCT No.: 2007-003198 - 22, NCT00646750
Freiburg ZNS-NHL Study
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: ZNS-00465, NCT00647049
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 09-0042 / 201101864, NCT00882895
Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 55
Sponsor: Other
Protocol IDs: L-149/2003, BfArM: A-7140-00-37/4021157, NCT00946374
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2292.00, NCI-2009-01302, X05287, P30CA015704, NCT00992446
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 0 to 75
Sponsor: NCI, Other
Protocol IDs: 2241.00, NCI-2009-01334, P30CA015704, NCT01008462
Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: NCI, Other
Protocol IDs: 2260.00, NCI-2010-00403, P30CA015704, FHCRC-2260.00, 6733, FHCRC-IR-6733, NCT00716066
High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NHL-ZNS-Rezidiv, NCT01148173
Start Over